Teva Pharmaceutical Industries (TEVA) Total Non-Current Liabilities (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Total Non-Current Liabilities for 18 consecutive years, with $16.5 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Non-Current Liabilities fell 23.24% year-over-year to $16.5 billion; the trailing twelve-month figure through Jun 2026 stood at $16.5 billion (down 23.24% YoY), and the FY2025 full-year result was $19.4 billion, down 6.87% from the prior year.
• Total Non-Current Liabilities slipped to $16.5 billion in Q2 2026 per TEVA's latest filing, from $18.3 billion in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $25.2 billion in Q1 2022 and bottomed at $16.5 billion in Q2 2026.
• Historically, Total Non-Current Liabilities has averaged $22.0 billion across 5 years, with a median of $21.7 billion in 2024.
• The sharpest annual moves came in 2023 and 2026: Total Non-Current Liabilities rose 0.44% in 2023, then decreased 23.24% in 2026.
• Over 5 years, Total Non-Current Liabilities stood at $23.9 billion in 2022, then retreated by 3.5% to $23.1 billion in 2023, then declined by 9.94% to $20.8 billion in 2024, then fell by 6.87% to $19.4 billion in 2025, then fell by 15.09% to $16.5 billion in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $16.5 billion, $18.3 billion, and $19.4 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.